论文部分内容阅读
Telaprevir是美国Vertex制药公司开发的一种丙型肝炎病毒(HCV)NS3/4A丝氨酸蛋白酶抑制剂,能抑制HCV的病毒复制。在欧洲和美国开展的国际多中心、双盲、对照III期临床试验结果显示,本品具有提高HCV感染患者持续病毒学应答(sustained viral response,SVR)的作用,确定了其治疗HCV感染的有效性及耐受性。2011年5月23日,美国FDA批准本品与聚乙二醇干扰素α和利巴韦林联用,用于治疗成人慢性丙型肝炎,商品名“Incivek”。
Telaprevir is a Hepatitis C Virus (HCV) NS3 / 4A serine protease inhibitor developed by Vertex Pharmaceuticals of the United States that inhibits HCV viral replication. The results of an international multicenter, double-blind, controlled phase III trial in Europe and the United States showed that this product has the effect of increasing sustained viral response (SVR) in HCV-infected patients and confirming its effectiveness in treating HCV infection Sexuality and tolerance. May 23, 2011, the United States FDA approved the goods with peginterferon alfa and ribavirin combined for the treatment of adult chronic hepatitis C, trade name “Incivek ”.